How do you find using the New Zealand Gazette? Please give your feedback by completing this survey.

Notice Type
Departmental
Notice Title

Provisional Consent to the Distribution of New Medicines

Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Rapamune
Active Ingredient: Sirolimus 2mg
Dosage Form: Coated tablet
New Zealand Sponsor: Wyeth (NZ) Limited
Manufacturers: Wyeth Pharmaceuticals Company, Barrios Pozo Hondos & Jobos, Guayama, Puerto Rico
Wyeth Pharmaceuticals Inc, Rouses Point, New York, United States of America
Note: This consent is valid for two years from the date of publication of this notice.
Product: Rilutek
Active Ingredient: Riluzole 50mg
Dosage Form: Tablet
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer: Aventis Pharma (Nenagh) Limited, Nenagh, Co. Tipperary, Ireland
Note: This consent is subject to the following condition:
? Rilutek can only be prescribed by specialist physicians who care for patients with motor neurone disease, neurologists and palliative care physicians.
Note: This consent is valid for two years from the date of publication of this notice.
Dated this 5th day of January 2006.
CYNTHIA MALING, Acting-Deputy Director-General, Public Health (pursuant to delegation given by the Minister of Health on the 6th day of July 2001).